P—Reference library
FDA-approved peptides
Regulatory status and a summary of what is reported and claimed.
4 of 29 peptides
| Name | Type | Compounding | Categories | Evidence level | Ev. vs. Hype | Momentum | WADA | Reviewed | + |
|---|---|---|---|---|---|---|---|---|---|
| Elamipretide SS-31 | FDA Approved | Approved product (not applicable) | Longevity & mitochondrial | Small/early human studies | Evidence Hype | Watch | Verify | 2026-10-30 | |
| Semaglutide Ozempic · Wegovy · Rybelsus | FDA Approved | Approved product (not applicable) | Metabolic / GLP-1 | Human RCTs (approved use) | Evidence Hype | Steady | Not prohibited | 2026-10-30 | |
| Tesamorelin Egrifta | FDA Approved | Approved product (not applicable) | Growth hormone axis | Human RCTs (approved use) | Evidence Hype | Steady | Prohibited | 2026-10-30 | |
| Tirzepatide Mounjaro · Zepbound | FDA Approved | Approved product (not applicable) | Metabolic / GLP-1 | Human RCTs (approved use) | Evidence Hype | Rising | Not prohibited | 2026-10-30 |